Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
LIS-1 by Xenothera for Natural Killer Cell Lymphomas: Likelihood of Approval
LIS-1 is under clinical development by Xenothera and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData,...
Data Insights
LIS-1 by Xenothera for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
LIS-1 is under clinical development by Xenothera and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to...